Jun 3, 2021 7:00am EDT Tonix Pharmaceuticals Presents Positive Results from Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
May 26, 2021 7:00am EDT Tonix Pharmaceuticals Announces Presentation of Two Posters at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
May 10, 2021 4:30pm EDT Tonix Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Highlights
Apr 21, 2021 7:00am EDT Tonix Pharmaceuticals to Participate in Fourth Annual Neuroscience Innovation Forum
Apr 19, 2021 7:00am EDT Tonix Pharmaceuticals Enters into Exclusive Worldwide Licensing Agreement with OyaGen to Develop Antiviral SARS-CoV-2 Inhibitor, TNX-3500, for the Treatment of COVID-19
Mar 22, 2021 2:30pm EDT Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA on TNX-601 CR for the Treatment of Major Depressive Disorder
Mar 19, 2021 7:00am EDT Tonix Pharmaceuticals Announces Issuance of U.S. Patent for Compositions and Uses of Tianeptine Oxalate Salt, the Active Ingredient of TNX-601 CR
